Bariatric-metabolic surgery more effective than lifestyle modification plus best medical care<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, May 3, 2023 (HealthDay News) — For patients with nonalcoholic steatohepatitis (NASH), bariatric-metabolic surgery is more effective than lifestyle modification plus best medical care, according to a study published online April 20 in The Lancet<\/em>.<\/p>\n Ornella Verrastro, Ph.D., from the Universit \u00a0 Cattolica del Sacro Cuore in Rome, and colleagues conducted a multicenter randomized trial involving patients aged 25 to 70 years with obesity, with or without type 2 diabetes, with histologically confirmed NASH. Participants were randomly assigned to lifestyle modification plus best medical care, Roux-en-Y gastric bypass, or sleeve gastrectomy (96 patients to each group).<\/p>\n The researchers found that the percentage of patients who met the primary end point of histological resolution of NASH without worsening of fibrosis at one-year follow-up was significantly higher in the Roux-en-Y gastric bypass and sleeve gastrectomy groups compared with the lifestyle modification group (56 and 57 percent, respectively, versus 16 percent) in the intention-to-treat analysis. In the per-protocol analysis, the primary end point was met by 70, 70, and 19 percent, respectively. There were no reports of deaths or life-threatening complications. Ten participants who had bariatric-metabolic surgery had severe adverse events; they did not require reoperations.<\/p>\n “The presence of NASH predicts a significant risk of complications and mortality in people with severe obesity and type 2 diabetes,” a coauthor said in a statement. “The results of this study provide a compelling case for prioritization of metabolic surgery in this patient population.”<\/p>\n Two authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n